How Can You Use Newer Therapies to Improve Clinical Decision-Making and Long-term Health Outcomes for Patients with Acute Myeloid Leukemia?
PROGRAM CHAIR
David Rizzieri, MD
Senior Vice President and Director
Novant Health Cancer Institute
Charlotte, NC
SPEAKER FACULTY
Alice S. Mims, MD, MSCR
Acute Leukemia Clinical Research Director
Associate Professor of Internal Medicine
The James Comprehensive Cancer Center
The Ohio State University
Columbus, OH
PROGRAM OVERVIEW
This activity will cover the assessment, monitoring, and treatment of Acute Myeloid Leukemia (AML).
TARGET AUDIENCE
This educational activity is intended for community oncologists and advanced practice oncology clinicians involved in the assessment, monitoring, and treatment of AML.
LEARNING OBJECTIVES
On completing the program, attendees should be able to:
- Evaluate how genetic and molecular markers aid in determining treatment strategies for patients with AML
- Assess clinical efficacy and safety data for newer formulations and novel targeted therapies used to manage patients with AML
- Personalize therapy for the treatment of newly diagnosed, relapsed/refractory (R/R), and secondary AML based on disease‐ and patient‐specific factors to communicate these treatment plans using shared decision-making strategies in the inpatient and outpatient settings
- Identify adverse events associated with AML treatment to appropriately prevent and/or manage these potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved and/or interested in the assessment, monitoring, and treatment of AML.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Faculty Member | Disclosures |
| David Rizzieri, MD | Dr. Rizzieri reports that he serves on the speakers bureaus for Celgene, Gilead, Seattle Genetics and Stemline, Novartis, Pfizer, Sanofi, Incyte, Morphosys, BMS, Jazz, Astellas. He is also on the advisory board for AbbVie, Agios, AROG, Bayer, Celgene, Gilead, Jazz, Novartis, Pfizer, Sanofi, Seattle Genetics, Stemline, Teva, Kite, Incyte, Amgen, Acrobiotech, Cellectis, and Chimerix, Inc. Dr. Rizzieri is a consultant for AbbVie, Agios, AROG, Bayer, Celgene, Celltrion, Mustang, Pfizer, Seattle Genetics, Stemline, Kite, Incyte, Amgen, Acrobiotech, Cellectis, and Chimerix, Inc and Gilead. He has also done Data Safety Monitoring for Chimerix, Inc. and Cellectis, in addition to the UCARRT Study. |
| Alice S. Mims, MD, MSCR | Dr. Mims reports that she serves as a consultant for AbbVie, Genentech, Jazz Pharmaceuticals, Daiichi Saynko, BMS, and Syndax Pharmaceuticals. |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer:
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Debra Gordon, MS, Medical Director for Med Learning Group has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete posttest and evaluation form online.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
RELEASE DATE: November 12, 2021
EXPIRATION DATE: November 12, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
